Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAVEN 4: Emicizumab Q4W in Hemophilia A
NCT03020160Phase 3Completed
- Sponsor
- Roche
- Start
- Jan 2017
- Primary completion
- Dec 2017
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 3 trial of emicizumab in hemophilia A, sponsored by Roche. Started Jan 2017; status: completed.
02
Drugs
emicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT03020160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03020160.